Matches in SemOpenAlex for { <https://semopenalex.org/work/W2074148834> ?p ?o ?g. }
- W2074148834 abstract "Overactive bladder (OAB)/ storage lower urinary tract symptoms (LUTS) have a high prevalence affecting up to 90% of men over 80 years. The role of sufficient therapies appears crucial. In the present review, we analyzed the mechanism of action of tolterodine extended-release (ER) with the aim to clarify its efficacy and safety profile, as compared to other active treatments of OAB/storage LUTS.A wide Medline search was performed including the combination of following words: LUTS, BPH, OAB, antimuscarinic, tolterodine, tolterodine ER. IPSS, IPSS storage sub-score and IPSS QoL (International Prostate Symptom Score) were the validated efficacy outcomes. In addition, the numbers of urgency episodes/24 h, urgency incontinence episodes/24 h, incontinence episodes/24 h and pad use were considered. We also evaluated the most common adverse events (AEs) reported for tolterodine ER.Of 128 retrieved articles, 109 were excluded. The efficacy and tolerability of tolterodine ER Vs. tolterodine IR have been evaluated in a multicenter, double-blind, randomized placebo controlled study in 1529 patients with OAB. A 71% mean reduction in urgency incontinence episodes was found in the tolterodine ER group compared to a 60% reduction in the tolterodine IR (p < 0.05). Few studies evaluated the clinical efficacy of α-blocker/tolterodine combination therapy. In patients with large prostates (prostate volume >29 cc) only the combination therapy significantly reduced 24-h voiding frequency (2.8 vs. 1.7 with tamsulosin, 1.4 with tolterodine, or 1.6 with placebo). A recent meta-analysis evaluating tolterodine in comparison with other antimuscarinic drugs demonstrated that tolterodine ER was significantly more effective than placebo in reducing micturition/24 h, urinary leakage episodes/24 h, urgency episodes/24 h, and urgency incontinence episodes/24 h. With regard to adverse events, tolterodine ER was associated with a good adverse event profile resulting in the third most favorable antimuscarinic. Antimuscarinic drugs are the mainstay of pharmacological therapy for OAB / storage LUTS; several studies have demonstrated that tolterodine ER is an effective and well tolerated formulation of this class of treatment.Tolterodine ER resulted effective in reducing frequency urgency and nocturia and urinary leakage in male patients with OAB/storage LUTS. Dry mouth and constipation are the most frequently reported adverse events." @default.
- W2074148834 created "2016-06-24" @default.
- W2074148834 creator A5012539089 @default.
- W2074148834 creator A5020683373 @default.
- W2074148834 creator A5029088271 @default.
- W2074148834 creator A5034704637 @default.
- W2074148834 creator A5042036655 @default.
- W2074148834 creator A5043068037 @default.
- W2074148834 creator A5047161343 @default.
- W2074148834 creator A5061191487 @default.
- W2074148834 creator A5080019020 @default.
- W2074148834 creator A5080620058 @default.
- W2074148834 creator A5083952077 @default.
- W2074148834 creator A5087124732 @default.
- W2074148834 date "2014-10-27" @default.
- W2074148834 modified "2023-10-13" @default.
- W2074148834 title "Tolterodine extended release in the treatment of male oab/storage luts: a systematic review" @default.
- W2074148834 cites W1507174593 @default.
- W2074148834 cites W1567603273 @default.
- W2074148834 cites W188009437 @default.
- W2074148834 cites W1967347194 @default.
- W2074148834 cites W1968860914 @default.
- W2074148834 cites W1969740456 @default.
- W2074148834 cites W1970710807 @default.
- W2074148834 cites W1978083855 @default.
- W2074148834 cites W1983094092 @default.
- W2074148834 cites W1986153368 @default.
- W2074148834 cites W1988807777 @default.
- W2074148834 cites W198934061 @default.
- W2074148834 cites W1995256786 @default.
- W2074148834 cites W2001645992 @default.
- W2074148834 cites W2008079238 @default.
- W2074148834 cites W2012719924 @default.
- W2074148834 cites W2018377518 @default.
- W2074148834 cites W2021702941 @default.
- W2074148834 cites W2024975356 @default.
- W2074148834 cites W2026599479 @default.
- W2074148834 cites W2033817897 @default.
- W2074148834 cites W2038693293 @default.
- W2074148834 cites W2044988410 @default.
- W2074148834 cites W2045828646 @default.
- W2074148834 cites W2049444610 @default.
- W2074148834 cites W2054263301 @default.
- W2074148834 cites W2059240022 @default.
- W2074148834 cites W2064430566 @default.
- W2074148834 cites W2073337601 @default.
- W2074148834 cites W2074323366 @default.
- W2074148834 cites W2078160609 @default.
- W2074148834 cites W2078997630 @default.
- W2074148834 cites W2079675222 @default.
- W2074148834 cites W2087702932 @default.
- W2074148834 cites W2088679190 @default.
- W2074148834 cites W2092473900 @default.
- W2074148834 cites W2092477693 @default.
- W2074148834 cites W2102524054 @default.
- W2074148834 cites W2109298103 @default.
- W2074148834 cites W2110991424 @default.
- W2074148834 cites W2116324813 @default.
- W2074148834 cites W2134121470 @default.
- W2074148834 cites W2142727765 @default.
- W2074148834 cites W2147987273 @default.
- W2074148834 cites W2148524234 @default.
- W2074148834 cites W2157094817 @default.
- W2074148834 cites W2161911161 @default.
- W2074148834 cites W2168942726 @default.
- W2074148834 cites W2346970262 @default.
- W2074148834 doi "https://doi.org/10.1186/1471-2490-14-84" @default.
- W2074148834 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4230346" @default.
- W2074148834 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25348235" @default.
- W2074148834 hasPublicationYear "2014" @default.
- W2074148834 type Work @default.
- W2074148834 sameAs 2074148834 @default.
- W2074148834 citedByCount "13" @default.
- W2074148834 countsByYear W20741488342016 @default.
- W2074148834 countsByYear W20741488342017 @default.
- W2074148834 countsByYear W20741488342018 @default.
- W2074148834 countsByYear W20741488342019 @default.
- W2074148834 countsByYear W20741488342020 @default.
- W2074148834 crossrefType "journal-article" @default.
- W2074148834 hasAuthorship W2074148834A5012539089 @default.
- W2074148834 hasAuthorship W2074148834A5020683373 @default.
- W2074148834 hasAuthorship W2074148834A5029088271 @default.
- W2074148834 hasAuthorship W2074148834A5034704637 @default.
- W2074148834 hasAuthorship W2074148834A5042036655 @default.
- W2074148834 hasAuthorship W2074148834A5043068037 @default.
- W2074148834 hasAuthorship W2074148834A5047161343 @default.
- W2074148834 hasAuthorship W2074148834A5061191487 @default.
- W2074148834 hasAuthorship W2074148834A5080019020 @default.
- W2074148834 hasAuthorship W2074148834A5080620058 @default.
- W2074148834 hasAuthorship W2074148834A5083952077 @default.
- W2074148834 hasAuthorship W2074148834A5087124732 @default.
- W2074148834 hasBestOaLocation W20741488341 @default.
- W2074148834 hasConcept C121608353 @default.
- W2074148834 hasConcept C126322002 @default.
- W2074148834 hasConcept C126894567 @default.
- W2074148834 hasConcept C142724271 @default.
- W2074148834 hasConcept C197934379 @default.
- W2074148834 hasConcept C204787440 @default.
- W2074148834 hasConcept C27081682 @default.
- W2074148834 hasConcept C2776235491 @default.